Cardiol Therapeutics Inc.

NASDAQ:CRDL

Drug Manufacturers - Specialty & Generic

Healthcare
$0.95 -0.47%

-$0.01 today

Market cap
$114.64M
Beta
0.80
P/E (TTM)
-4.5
EPS (TTM)
-$0.33
52W Low $0.88High $1.71

Volume 0.31M

Average 0.68M

CRDL Interest Expense

Cost of servicing the company's debt during the period.

Cardiol Therapeutics Inc.NASDAQ: CRDL

Interest Expense · Q1 FY2026 · quarter ended Mar 2026

Interest expense remains negative

Q1 FY2026 interest expense was CA$0, compared with CA$0 a year earlier. Trailing-twelve-month interest expense was CA$0.

Context

  • Interest expense increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly interest expense holds near CA$0 or moves back toward the trailing-twelve-month quarterly average of CA$0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$0— QoQ
Last fiscal yearDec 2025
CA$0— YoY
LTMMar 2026
CA$0— YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Interest Expense history

CAD · from the income statement

Latest · FY2025
0 CAD
Year-over-year change
—

Interest Expense vs competitors

How CRDL compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest expense is compared through growth and share of revenue rather than absolute size.
CRDL Competitors
Interest Expense for CRDL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INCRInterCure Ltd.LTM Jun 2025₪8.91M ILS—+10.2%3.7%
ASRTAssertio Holdings, Inc.LTM Mar 2026$3.09M USD+5.1%-27.2%3.0%
IMAImageneBio IncLTM Mar 2026$96K USD———
HYPRHyperfine, Inc.LTM Mar 2026$83K USD——0.5%
IFRXInflaRx N.V.LTM Mar 2026€48.66K EUR+115.0%-5.9%165.9%
CRDLCardiol Therapeutics Inc.LTM Mar 2026CA$0 CAD———
VANIVivani Medical, Inc.LTM Mar 2026$0 USD———
MBOTMicrobot Medical Inc.LTM Mar 2026$0 USD——0.0%
CNTBConnect Biopharma Holdings LimitedFY2025$0 USD——0.0%
KLRSKalaris Therapeutics IncLTM Mar 2026$0 USD-100.0%+83.1%—
Peer median (excluding CRDL) —+5.1%+2.1%1.8%

Competitors are the stored peer set for CRDL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue62.27K0000
Cost of Revenue174.26K162.23K187.38K00
Gross Profit(112K)(162.23K)(187.38K)00
Gross Margin-179.9%————
Research & Development8.59M13.99M10.73M14.01M14.02M
Selling, General & Admin21.86M16.34M11.55M25.89M20.2M
Operating Expenses30.46M30.33M22.29M40.28M34.32M
Depreciation & Amortization174.26K162.23K187.38K162.11K101.98K
EBITDA(24.84M)(22.66M)(21.04M)(36.52M)(33.72M)
EBITDA Margin-39891.0%————
Operating Income(30.57M)(30.49M)(22.47M)(40.28M)(34.32M)
Operating Margin-49092.4%————
Interest Income106K1.24M2.04M1.19M726.4K
Interest Expense00000
Other Income / Expenses5.56M7.68M1.25M3.6M497.42K
Income Before Tax(25.01M)(22.82M)(21.22M)(36.68M)(33.82M)
Pre-Tax Margin-40170.9%————
Income Tax Expense00000
Net Income(25.01M)(22.82M)(21.22M)(36.68M)(33.82M)
Net Margin-40170.9%————
EPS (Basic)(0.73)(0.49)(0.44)(0.51)(0.39)
EPS (Diluted)(0.73)(0.49)(0.44)(0.51)(0.39)
Weighted Avg Shares43.22M62.51M64.46M71.57M86.99M
Weighted Avg Shares (Diluted)43.22M62.51M64.46M71.57M86.99M

Cardiol Therapeutics Inc.

NASDAQ:CRDL

Intrinsic Alpha fair value

Locked

Current Price

$0.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.